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Psoriatic arthritis

Original article
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Abstract

Objective To assess the long-term (3 year) efficacy and
safety of secukinumab in patients with active psoriatic
arthritis (PsA) in the extension phase of the FUTURE 1
study (NCT01892436).
Methods Following the 2-year core trial, eligible patients
receiving subcutaneous secukinumab 150 or 75 mg
entered a 3-year extension phase. Results are presented
for key efficacy and safety endpoints at week 156.
Results In total, 460 patients entered the extension
study; 308 patients originally randomised to secukinumab
were assessed for efficacy. Sustained improvements in
all efficacy endpoints were achieved with secukinumab
through week 156. Overall, 76.8%/54.9% (secukinumab
150 mg) and 65.2%/39.0% (secukinumab 75 mg) of
patients achieved an American College of Rheumatology
(ACR) 20/50 response (multiple imputation data); ACR20
responses were sustained irrespective of previous antitumour necrosis factor exposure. Improvements in quality
of life and physical function were also sustained through
week 156. Radiographic results (observed data; van der
Heijde modified total Sharp score (mTSS)) showed that
78.1% (secukinumab 150 mg) and 74.8% (secukinumab
75 mg) of patients had no radiographic progression (≤0.5
increase in mTSS) through week 156. Exposure-adjusted
incidence rates for selected adverse events per 100
patient-years (secukinumab 150/75 mg) were serious
infections (1.7/1.6), Candida infections (1.4/0.7), Crohn’s
disease (0/0.3), ulcerative colitis (0/0.3) and major adverse
cardiac events (0.3/0.8).
Conclusion Subcutaneous secukinumab provided
sustained improvements in the signs and symptoms,
quality of life and physical function of patients with active
PsA with low rate of radiographic disease progression
through 3 years. Secukinumab was well tolerated with no
new safety signals.
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Introduction
Psoriatic arthritis (PsA) is a chronic, inflammatory disease characterised by peripheral

Key messages

What is already known about this subject?
►► Secukinumab, a fully human monoclonal IgG1κ an-

tibody that selectively neutralises IL-17A, provided
sustained improvements in the signs and symptoms
of active psoriatic arthritis (PsA) in phase III FUTURE
1 study over 2 years.

What does this study add?
►► Secukinumab 150 mg (approved dose) sustained or

further improved the clinical responses in patients
with active PsA over 3 years in FUTURE 1 study, with
a low rate of radiographic disease progression and
safety profile consistent with previous reports.

How might this impact on clinical practice?
►► This long-term (3-year) data for secukinumab in PsA

adds to the growing body of evidence supporting the
use of IL-17 inhibitors in PsA, as recognised in the
guidelines of European League Against Rheumatism
and Group for Research and Assessment of Psoriasis
and Psoriatic Arthritis recommendations.

arthritis, axial disease, dactylitis, enthesitis,
and skin and nail psoriasis.1 It can be associated with more serious comorbidities
such as cardiovascular disease, metabolic
syndrome and diabetes,2–4 and has a substantial impact on quality of life, physical function and work productivity.5 Management of
PsA should ideally aim to minimise articular
pain, enthesitis, structural damage, disability
and dermatological symptoms.1 6–8 The introduction of anti-tumour necrosis factor-α
inhibitors (anti-TNF agents) has significantly
improved outcomes among patients with
PsA,6 9–11 but a proportion of patients have an
inadequate response or poor tolerability to
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these agents.3 12 Secukinumab, a fully human monoclonal
antibody that selectively neutralises interleukin IL-17A,13
has been shown to have significant efficacy in the treatment of ankylosing spondylitis,13 14 moderate to severe
psoriasis15 and PsA,16–18 demonstrating a rapid onset of
action and sustained responses with an acceptable safety
profile across the three indications.19 20
In the randomised, placebo-controlled, phase III
FUTURE 1 core study, secukinumab demonstrated rapid,
significant and sustained reductions in the signs and
symptoms of PsA, and inhibited radiographic progression through 2 years of treatment.16 21 The ongoing
FUTURE 1 extension trial is a 3-year extension of the
2-year core trial, assessing the effect of secukinumab
on the signs and symptoms, structural damage, physical
function and quality of life of patients with active PsA, in
addition to evaluating long-term safety. Here, we present
efficacy and safety results of all doses (secukinumab 150
mg (approved dose) and 75 mg) assessed in the FUTURE
1 study through 3 years (2 years of the core study plus 1
year of the extension).
Methods
Study population
Detailed patient eligibility criteria have been reported
previously.16 Briefly, patients were ≥18 years, with active
PsA according to the Classification Criteria for Psoriatic Arthritis,22 with moderate to severe symptoms for
≥6 months, ≥3 tender joints of 78 and ≥3 swollen joints
of 76, despite previous treatment with nonsteroidal
anti-inflammatory drugs, disease-modifying anti-rheumatic drugs or anti-TNF agents. Concomitant use of
oral glucocorticoids (up to 10 mg/day of prednisone or
equivalent) and methotrexate (up to 25 mg/week) was
permitted. Patients were excluded if they had previous
therapy with biologic agents other than anti-TNF agents,
treatment with more than three anti-TNF agents, active
inflammatory disease other than PsA or active/history of
ongoing infection. The study was approved by the institutional review board or ethics committee at each participating site (Swedish Medical Centre and University of
Washington (1143210), Dallas VAMC and University
of Texas Southwestern Medical Centre (#IRB 14-025),
Barts Health NHS Trust (13/WM/0365), University of
Erlangen-Nuremberg (AZ: EK-13/081), Monash University (2013-08-423), University of Hasselt and Maastricht
University Hospital (2013/1062); online supplementary
table 1) and was conducted according to the Declaration
of Helsinki.23
Study oversight and design
The randomised, double-blind FUTURE 1 study
(NCT01892436) was conducted across 104 sites in North
and South America, Europe, the Middle East, Australia and
Asia, the design of which has been previously reported.16
Briefly, eligible patients were initially randomised to
receive secukinumab 10 mg/kg intravenous (IV) loading
2

dose at baseline and weeks 2 and 4, followed by subcutaneous (SC) secukinumab 150 mg or 75 mg every 4 weeks
from week 8. Placebo was given using the same IV-to-SC
dosing schedule. At week 16, placebo-treated patients
were re-randomised to receive SC secukinumab 150 mg
or 75 mg from either week 16 for placebo non-responders
(<20% improvement from baseline in both tender
and swollen joints) or week 24 for placebo responders.
Randomisation was stratified by previous anti-TNF status,
with patients being anti-TNF-naïve or anti-TNF-experienced (incomplete responders who had active disease
despite having received an anti-TNF agent for ≥3 months,
or who had stopped treatment due to safety and tolerability reasons). At the end of the 2-year core trial, eligible
patients entered the 3-year extension phase. From week
156, patients not adequately responding to secukinumab
75 mg could be up-titrated to secukinumab 150 mg, at
the discretion of investigators. See online supplementary
figure 1 for the extension study design.
Endpoints and assessments
Efficacy results at week 156 are reported for patients
who were originally randomised to 10 mg/kg IV loading
followed by SC 150 mg and 75 mg maintenance with
secukinumab. The primary efficacy endpoints of this
extension study were the proportion of patients treated
with secukinumab 150 mg and 75 mg achieving an
American College of Rheumatology (ACR) 20/50/70
response over time.24 Week 156 assessments also included
the proportion of patients achieving Psoriatic Area
and Severity Index (PASI) 75 responses, resolution of
dactylitis and enthesitis and proportion of patients with
minimal disease activity (MDA). Changes from baseline
in Disease Activity Score in 28 joints using C reactive
protein (DAS28-CRP), Health Assessment Questionnaire–Disability Index (HAQ-DI), Medical Outcome
Short Form (36) Health Survey (SF-36) Physical Component Summary (PCS) and Mental Component Summary
(MCS), and radiographic progression (measured by the
van der Heijde modified total Sharp score (mTSS), which
is the sum of erosion and joint space narrowing (JSN)
scores).25 X-rays of the hands, wrists and feet, performed
at baseline and week 156, were read centrally by two
independent readers blinded to the treatment arms.
The mean score was used for all analyses. Radiographic
non-progressors were defined as patients with a change
from baseline of ≤0.5 in mTSS during the considered
period, as per guideline recommendations.26 Long-term
safety and tolerability was assessed over the treatment
period by monitoring the frequency of treatment-emergent adverse events (AEs), serious AEs, laboratory abnormalities and vital signs.
Statistical analyses
Sample size calculation estimated that 600 patients
(200 in each secukinumab group and 200 in the
placebo group) were sufficient to meet primary and
key secondary endpoints. Analysis of primary and other
Mease PJ, et al. RMD Open 2018;4:e000723. doi:10.1136/rmdopen-2018-000723
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efficacy endpoints of the core trial have been reported
previously.16 It was estimated that 460–520 patients would
be eligible for enrolment in this extension study.
Evaluations of efficacy were performed on patients
enrolled in the extension with at least one efficacy
assessment during the extension and who were originally randomised to 10 mg/kg IV loading at baseline
and weeks 2 and 4, followed by SC 150 mg and 75 mg
maintenance with secukinumab starting at week 8. Efficacy data from patients who discontinued the study were
considered as end of treatment period results. No formal
hypotheses were planned in this extension study. In the
current analysis, missing binary variables up to week 156
were imputed using multiple imputation. Summaries of
continuous variables are as observed and presented as
mean±SD. Dactylitis and enthesitis were evaluated using
multiple imputation in the subgroup of patients with
these symptoms at baseline. PASI response was evaluated
in the subgroup of patients with at least 3% of the body
surface area affected by psoriatic skin involvement.
Joint structural damage (changes from baseline in
mTSS scores, erosion scores and JSN scores) and proportion of radiographic non-progressors were analysed using
observed data based on all evaluable patients with data at
both baseline and week 156.
Predefined subgroup analyses were carried out on the
basis of previous anti-TNF therapy (anti-TNF-naïve or
anti-TNF-experienced) for key efficacy endpoints.
Safety analysis included all patients (core and extension study phase) who received ≥1 dose of secukinumab,
with patients analysed for safety according to the actual

Figure 1

treatment they received. As safety was collected over the
treatment period and included data past week 156, safety
analyses included patients who up-titrated from 75 mg
to 150 mg; therefore, patients who were up-titrated were
counted in either secukinumab group depending on the
timing of the event. Data for selected AEs are presented
as ted incidence rates (EAIRs) exposure-adjusted incidence rate (EAIR) per 100 patient-years.
Results
Patients
Of the 606 patients originally randomised in the FUTURE
1 core trial, 460 (75.9%) patients entered the extension
study (secukinumab 150 mg (N=162), secukinumab 75
mg (N=148), placebo then secukinumab (N=150)).
Figure 1 shows a breakdown of patients who entered
the extension study. Three patients who were originally
randomised to secukinumab and who discontinued the
study were not part of the efficacy analyses due to the lack
of efficacy assessment during the extension study; reasons
for discontinuation were sudden cardiac death (150 mg
arm), patient decision (75 mg arm) and development of
squamous cell carcinoma of the pharynx (75 mg arm).
Within the full analysis set (FAS) population, the
reasons for discontinuation included patient decision
(n=7), AEs (n=5), lack of efficacy (n=5), physician decision (n=2), pregnancy (n=2) and loss to follow-up (n=1).
The patient demographics and baseline disease characteristics of patients entering the long-term extension
phase were similar across the 150 mg and 75 mg arms

Patient disposition up to week 156. FAS, full analysis set; n, number of patients; SC, subcutaneous.
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Table 1 Demographics and baseline characteristics of
patients originally randomised to secukinumab who entered
the extension phase

Characteristic*

Secukinumab
10 mg/kg
IV→150 mg SC
(N=161)

Secukinumab
10 mg/kg
IV→75 mg SC
(N=147)

Age (years)

49.5±11.7

48.9±11.8

Female, n (%)

83 (51.6)

81 (55.1)

Weight (kg)

83.34±19.43

83.43±19.50

8.19±8.33

7.66±8.31

Time (years) since first
diagnosis of PsA

Disease history and baseline characteristics
Anti-TNF-naïve, n (%)

120 (74.5)

110 (74.8)

Methotrexate use, n (%)

98 (60.9)

91 (61.9)

Systemic glucocorticoid use,
n (%)

28 (17.4)

22 (15.0)

TJC (78 joints)

24.1±16.95

21.6±15.63

SJC (76 joints)

12.7±9.81

11.8±9.91

Psoriasis (≥3% body surface
area), n (%)

89 (55.3)

82 (55.8)

Presence of dactylitis, n (%)

83 (51.6)

77 (52.4)

Presence of enthesitis, n (%)

99 (61.5)

91 (61.9)

*Results are mean±SD unless otherwise stated.
IV, intravenous; N, number of randomised patients; n, number
of patients; PsA, psoriatic arthritis; SC, subcutaneous; SJC,
swollen joint count; TJC, tender joint count; TNF, tumour
necrosis factor.

(table 1). For secukinumab 150 mg and 75 mg, more
than half the patients (55.3% and 55.8%) had psoriasis
affecting at least 3% of their body surface area; 51.6%
and 52.4% had dactylitis and 61.5% and 61.9% had
enthesitis, respectively. A total of 25.5% and 25.2% were
anti-TNF-experienced; 18.6% and 16.3% had received
one anti-TNF therapy and 6.8% and 8.8% had received
two or more anti-TNF therapies in the secukinumab 150
mg and 75 mg arms, respectively. A total of 60.9% and
61.9% were receiving concomitant methotrexate in the
secukinumab 150 mg and 75 mg arms, respectively.
Efficacy
Out of 460 (75.9%) patients who entered the extension
trial, 435 (95.2%) completed 156 weeks (ie, 52 weeks of
the extension). Sustained improvements in efficacy were
observed during this extension study, with 76.8% and
65.2% of patients treated with secukinumab 150 mg and
75 mg achieving an ACR20 response and 54.9/32.9%
and 39.0/26.0% achieving ACR50/70 responses through
week 156, respectively (figure 2A and table 2). ACR20
response rates were sustained through week 156, irrespective of previous anti-TNF agent exposure, with ACR20
responses achieved by 81.0% and 67.3% of anti-TNFnaïve patients and 61.5% and 55.6% of anti-TNF-experienced patients treated with secukinumab 150 mg and 75
mg, respectively (figure 2B). Resolution of dactylitis and
4

enthesitis were sustained through week 156, with 88.1%
and 86.8% of patients achieving dactylitis resolution and
76.7% and 74.8% achieving enthesitis resolution in the
150 mg and 75 mg arms, respectively (table 2 and online
supplementary figure 2). Secukinumab also demonstrated sustained improvement in PASI 75 responses and
DAS28-CRP through week 156 (table 2). Proportion of
patients with MDA response at week 156 was 43% and
33% in secukinumab 150 mg and 75 mg, respectively
(table 2). Improvements in physical and mental component of quality of life (SF-36 PCS and SF-36 MCS) and
in physical function (HAQ-DI) were sustained over the
treatment period for secukinumab 150 mg and 75 mg
(table 2).
Results from patients with evaluable X-ray assessments
demonstrated that 78.1% (100/128) and 74.8% (92/123)
of patients had no radiographic progression (mTSS score
≤0.5) from baseline to week 156, in the 150 mg and in
the 75 mg arms, respectively (table 3A). Mean changes in
mTSS score from baseline to week 156 for patients in the
150 mg and 75 mg arms are shown in table 3B. Subgroup
analysis by anti-TNF status demonstrated that in patients
with evaluable X-ray assessments, 78/100 (78.0%) and
73/94 (77.7%) of anti-TNF-naïve patients and 22/28
(78.6%) and 19/29 (65.5%) of anti- TNF-experienced
patients were radiographic non-progressors in the 150
mg and 75 mg groups, respectively (table 3A). Changes
in mTSS score from baseline to week 156 in anti-TNFnaïve patients remained low (table 3B).
Safety
The incidence of AEs and serious AEs are presented in
table 4. The EAIR per 100 patient-years of AEs in the
any secukinumab 150 mg and 75 mg arms was 158.8 and
128.9; the rate of serious AEs was 9.3 and 6.4, respectively.
The most commonly reported AEs with secukinumab
were infections and infestations, musculoskeletal and
connective tissue disorders and gastrointestinal disorders, which were stable over the long-term period of
this study. EAIRs for serious infections and infestations,
Crohn’s disease, ulcerative colitis, major adverse cardiovascular events (MACE), inflammatory bowel disease
and neoplasms (benign, malignant or unspecified) for
secukinumab 150 mg and 75 mg were consistent with
previous trials and are reported in table 4. Candida infections were reported in 12 (EAIR=1.4) and 5 (EAIR=0.7)
patients in the any secukinumab 150 mg and 75 mg arms,
respectively. All cases of Candida infection were mild to
moderate in severity and resolved spontaneously with
standard treatment or with non-drug therapy; no cases
led to discontinuation of secukinumab treatment. One
case of reactivation of latent tuberculosis was reported in
the any secukinumab 150 mg arm.
Deaths (spontaneous acute myocardial infarction (n=1)
and cardiac failure (n=1)) were reported in two patients
with concomitant disease in the any secukinumab 150
mg arm. Deaths occurred in three patients in the any
secukinumab 75 mg arm including two patients (stroke
Mease PJ, et al. RMD Open 2018;4:e000723. doi:10.1136/rmdopen-2018-000723
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Figure 2 (A) ACR20/ACR50 response rates through week 156 in all patients originally randomised to secukinumab. (B)
ACR20 response rates through week 156 in anti-TNF-nave and anti-TNF-experienced patients. Multiple imputation applied
to missing variables through week 156. ACR, American College of Rheumatology; IV, intravenous; n, number of patients; SC,
subcutaneous; TNF, tumour necrosis factor.

(n=1) and myocardial infarction (n=1)) with concomitant disease and in one patient who developed squamous
cell carcinoma during the study and discontinued secukinumab treatment on receiving the diagnosis.
Discussion
Results from the first year of the phase III FUTURE 1
extension study have furthered our understanding of the
role of secukinumab in the long-term treatment of PsA.
Secukinumab demonstrated sustained improvements
in the signs and symptoms, function and health-related
quality of life in patients with active PsA, in addition to
low rate of radiographic disease progression through 3
years of treatment. Patient retention rates throughout
this trial were high with 95.2% of the FAS population
completing the 156-week treatment period, supporting
the sustained efficacy and tolerability of secukinumab.
These are the first 3-year findings reported for secukinumab in PsA and the data add to the growing body
of evidence supporting the use of IL-17 inhibitors in
PsA, as recognised in the guidelines from the European
League against Rheumatism and Group for Research and
Mease PJ, et al. RMD Open 2018;4:e000723. doi:10.1136/rmdopen-2018-000723

Assessment of Psoriasis and Psoriatic Arthritis management recommendations.7 27
Consistent with previous reports, clinical benefits with
secukinumab were observed regardless of prior exposure
to anti-TNF therapy,28 with better responses observed in
anti-TNF-naïve patients supporting it use as a treatment
for patients with PsA naïve to anti-TNF therapy and those
who have experienced an inadequate response or intolerance to these agents.6 29–32
The IL-17 pathway plays a role in irreversible structural
damage experienced during inflammatory arthritis,33–36
as indicated by the increased presence of IL-17+CD8+
T-cells in the joints of patients with PsA.33 Previously
published results from the FUTURE 1 study have demonstrated that secukinumab significantly inhibited radiographic progression in patients with PsA versus placebo at
week 24,37 with sustained inhibition through 2 years.16 28
Results reported here extend these findings up to 3 years
of treatment.
The safety profile of secukinumab in this trial was
consistent with previous reports in patients with PsA
and moderate-to-severe plaque psoriasis, with no new
5
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Table 2 Secondary efficacy endpoints at weeks 52, 104
and 156 in patients originally randomised to secukinumab

Variable
PASI 75*†, %
responders

DAS28-CRP‡,
mean change from
baseline ±SD

Secukinumab
10 mg/kg
IV→150 mg SC
Week (N=161)

Secukinumab
10 mg/kg
IV→75 mg SC
(N=147)

52

87.6

75.6

104

81.9

72.2

156

75.6

58.6

52

−1.82±1.14

−1.95±1.14

104

−1.81±1.23

−1.86±1.22

156

−1.94±1.32

−1.85±1.49

SF-36 PCS‡,
mean change from
baseline ±SD

52

6.83±7.42

5.87±7.04

104

6.25±8.04

5.33±7.22

156

6.01±8.53

5.50±7.27

SF-36 MCS‡,
mean change from
baseline ±SD

52

6.60±9.48

4.52±8.81

104

5.90±9.75

4.45±8.88

156

5.48±10.29

3.34±9.64

HAQ-DI‡, mean
change from
baseline ±SD
ACR70*, %
responders

Dactylitis
resolution*§ (%)

Enthesitis
resolution*§ (%)

MDA*, %
responders

52

−0.47±0.51

−0.47±0.60

104

−0.43±0.56

−0.42±0.60

156

−0.43±0.57

−0.42±0.62

52

27.5

27.4

104

28.1

23.7

156

32.9

26.0

52

82.0

84.4

104

86.5

88.6

156

88.1

86.8

52

74.8

75.6

104

74.5

80.3

156

76.7

74.8

52

42.5

37.8

104

40.0

36.5

156

42.9

33.3

*Multiple imputation applied to missing variables through week
156.
†Analysis performed in randomised patients with psoriasis
affecting ≥3% body surface area (psoriasis subset).
‡Observed data through week 156.
§Resolution of dactylitis and enthesitis are shown for patients
with these symptoms at baseline (dactylitis: N=83 (150 mg) and
77 (75 mg); enthesitis: N=99 (150 mg) and 91 (75 mg). Results
are mean±SD unless otherwise stated.
ACR, American College of Rheumatology; DAS28-CRP,
Disease Activity Score in 28 joints using C-reactive protein;
HAQ-DI, Health Assessment Questionnaire–Disability Index; IV,
intravenous; MCS, mental component summary; MDA, minimal
disease activity; N, number of randomised patients; PASI,
Psoriasis Area and Severity Index; PCS, physical component
summary; SC, subcutaneous; SF-36, medical outcomes study
36-item Short Form-36 Health Survey.

or unexpected safety signals observed.15–17 The most
common AEs observed (infections and infestations,
musculoskeletal and connective tissue disorders, and
gastrointestinal disorders) and serious AEs are consistent
6

Table 3A Proportion of radiographic non-progressors
Secukinumab
10 mg/kg IV→150
mg SC
(N=161)

Secukinumab
10 mg/kg IV→75
mg SC
(N=147)

Radiographic nonprogressors, n/M (%)

100/128 (78.1)

92/123 (74.8)

Anti-TNF-naïve
patients

78/100 (78.0)

73/94 (77.7)

Anti-TNF-experienced
patients
22/28 (78.6)

19/29 (65.5)

IV, intravenous; M, number of patients who have a nonmissing response status in the treatment group; n, number of
patients who are non-progression responders (non-progression
responders were patients with a change from baseline of
≤0.5 in van der Heijde modified Total Sharp Score during the
considered period); SC, subcutaneous; TNF, tumour necrosis
factor.

with data from previous reports in patients receiving
secukinumab and placebo.16
Patients with PsA have been reported to have a possible
elevated risk of cardiovascular disease38–40 when treated
with anti-IL-12/23 agents,41 42 and thus cardiovascular AEs
are of interest in patients treated with biological agents.
In our study, the EAIRs of MACE were 0.3 and 0.8 in the
any secukinumab 150 mg and 75 mg groups, respectively.
This is in line with previously reported rates of MACE
in secukinumab-treated patients, including those from
the FUTURE 1 core study,15 16 28 and corroborate results
from a recent meta-analysis showing a low overall MACE
rate in patients with psoriasis who were treated with
the IL-17A inhibitors, secukinumab and ixekizumab.43
Candida infections observed during this study are consistent with results from phase III studies, including the
FUTURE 1 core study, in patients with PsA17 28 and psoriasis.15 All cases were mild to moderate in severity, did not
lead to discontinuation and were managed with standard
antifungal therapy. Increased rate of Candida infections
is likely attributable to the role of IL-17 in host defense
against fungal infections, particularly at mucosal sites.44
Other AEs of special interest in this study, including
Crohn’s disease and ulcerative colitis, were low and in line
with previously reported findings, including those from
the FUTURE 1 core study.16 20 They also confirm results
from a recent review of phase II and III studies where
patients with PsA treated with secukinumab (up to 112
weeks) had EAIRs of 0.07 for Crohn’s disease and 0.14 for
ulcerative colitis.45 No suicides or suicide ideation were
reported during this study.
While this study was not specifically designed to
examine the psychological impact of secukinumab treatment on patients with PsA, an improvement in emotional
role functioning and mental health was observed with
secukinumab treatment, as assessed by the patient-reported SF-36 MCS.46
Limitations of this study included a lack of a long-term
comparator due to the fact that long-term treatment with
Mease PJ, et al. RMD Open 2018;4:e000723. doi:10.1136/rmdopen-2018-000723
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Table 3B Mean change in X-ray assessments from
baseline to week 156 (mTSS score, erosion score and JSN
score—evaluable cases, observed data)

X-ray
measurement*

Secukinumab
10 mg/kg
IV→150 mg SC
(N=161)

Secukinumab
10 mg/kg
IV→75 mg SC
(N=147)

128

123

Overall
No of patients
evaluated
 mTSS score

Baseline

 Erosion score
 JSN score

Exposure to study treatment 754.0±509.4
(days), mean±SD
Death, n (%)

Any
secukinumab
75 mg*
(N=292)
940.1±340.3

2 (0.5)

3 (1.0)

20 (4.6)

20 (6.8)

321 (158.8)

248 (128.9)

73 (9.3)

45 (6.4)

Discontinuation due to AEs,
n (%)

16.3±32.30

Change†

1.9±8.49

2.0±6.44

Any AEs, n (EAIR)

Baseline

8.1±16.88

7.7±14.63

Any serious AEs, n (EAIR)

Change†

1.1±5.31

1.0±3.57

AEs of special interest, n (EAIR)

Baseline

8.8±18.36

8.6±18.43

15 (1.7)

12 (1.6)

Change†

0.8±3.54

1.0±3.42

 Serious infections and
infestations
 
Candida infections

12 (1.4)

5 (0.7)

 Crohn's disease

0 (0)

2 (0.3)

 Ulcerative colitis

0 (0)

1 (0.1)

 MACE

3 (0.3)

6 (0.8)

(N=120)

No of patients
evaluated

100

(N=110)
94

Baseline

13.1±28.35

12.5±30.80

Change†

1.1±4.49

1.4±5.29

 Erosion score
 

Baseline

6.7±14.67

5.8±13.80

Change†

0.7±3.66

0.7±2.80

 JSN score
 

Baseline

6.4±14.30

6.7±17.58

Change†

0.4±1.16

0.7±2.78

(N=41)

(N=37)

Anti-TNFexperienced
patients
No of patients
evaluated
 mTSS score
 

AEs

Any
secukinumab
150 mg*
(N=434)

16.9±34.52

Anti-TNF-naïve
patients

 mTSS score
 

Table 4 AEs and serious AEs across entire treatment
period

Baseline

28

29

30.5±49.09

28.5±34.51

Change†

5.1±15.88

4.1±9.07

 Erosion score
 

Baseline

13.3±22.72

13.8±15.81

Change†

2.7±8.96

2.2±5.25

 JSN score
 

Baseline

17.2±27.21

14.8±20.08

Change†

2.4±7.11

1.8±4.93

Values are as mean±SD.
*Observed data.
†
Change from baseline to week 156. Only patients with a value
at each time point are presented.
IV, intravenous; JSN, joint space narrowing; mTSS, van der
Heijde modified total Sharp score; N, total number of patients
in specified group; SC, subcutaneous; TNF, tumour necrosis
factor.

placebo is considered unethical; the placebo-controlled
period of the core trial was, therefore, only up to week
16. There was no active comparator included and results
could be potentially biased as patients remaining in the
study are those patients benefiting from secukinumab.
While efficacy responses in the current study were
sustained irrespective of previous anti-TNF exposure,
patients eligible for inclusion in this study could have
Mease PJ, et al. RMD Open 2018;4:e000723. doi:10.1136/rmdopen-2018-000723

*Includes all patients who were administered with at least one
dose of study treatment during the core or the extension study.
Patients who were up-titrated (N=139) were counted in either
secukinumab groups depending on the timing of the event. If a
patient experienced an AE after up-titration, the corresponding
AE was counted at the up-titrated dose.
AE data presented as n (EAIR per 100 patient-years) unless
otherwise stated.
AE, adverse event; EAIR, exposure-adjusted incidence rate;
IV, intravenous; MACE, major adverse cardiac events; SC,
subcutaneous.

been treated with no more than three anti-TNF agents;
this may be viewed as a limitation of the study.
In summary, secukinumab provided sustained improvements across multiple domains of PsA including signs and
symptoms, quality of life and physical function in patients
with active disease, in addition to low rate of radiographic
disease progression through 3 years of treatment. The
results confirmed a favourable and consistent safety
profile through 3 years, which is comparable with that
reported through 2 years in the core trial. Overall, the
results of this extension study provide further supporting
evidence for the long-term use of secukinumab in the
treatment of patients with PsA.
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